https://www.selleckchem.com/products/Estrone.html
Five patients (38%) in the reaction group and 4 patients (31%) in the no reaction group had a documented mutation in one or both BRCA genes (p = 1.0. No significant differences were found in terms of reaction severity or symptoms, and timing of reaction after dose administration. Incidence of thyroid disorder was significantly higher among patients who experienced a hypersensitivity reaction (1 (4%) vs 10 (45%); p = 0.004). BRCA mutation status was not associated with an increased risk of carboplatin hypersensitivity in our patient po
Like
Comment
Share
